Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
111, Inc. posted a 16.7% revenue drop in Q3 2025 but stayed profitable, boosted by a strategic shift and a new AI drug platform.
111, Inc. reported third-quarter 2025 financial results showing a 16.7% revenue drop to RMB3.0 billion, but maintained non-GAAP profitability for the third straight quarter with RMB0.2 million in income from operations and RMB1.1 million in net income.
Operating expenses fell 13.4% to RMB180.3 million, and the company generated RMB38.1 million in operating cash flow for the quarter.
This follows a strategic shift to an asset-light model after divesting three self-operated units, now fulfillment partners, improving liquidity.
The "MANTIANXING" supply chain initiative boosted gross merchandise value by 20.5% and customer count by 31% from Q2.
The company plans to launch an AI-powered pharmaceutical procurement platform to enhance supply chain efficiency.
111, Inc. registró una caída de ingresos del 16.7% en el tercer trimestre de 2025, pero se mantuvo rentable, impulsada por un cambio estratégico y una nueva plataforma de fármacos de IA.